The Plasma Level of Branded Generic Apixaban in Patients with Atrial Fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230410004

Enrollment

100

Registered

2023-04-10

Start date

2023-04-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation (AF) Atrial fibrillation anti-factorXa activity generic apixaban efficiency

Interventions

Apixaban is DOACs (direct oral anticoagulants) that have become the mainstay of anticoagulation in patients with atrial fibrillation (AF) to prevent ischemic stroke.

Experimental Drug

Generic Apixaban

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults aged > 20 years with clinical AF who are eligible for DOAC according to latest clinical practice guidelines.

Exclusion criteria

Exclusion criteria: (1) Received another DOAC before this study (2) Moderate and severe mitral valve stenosis (3) Underwent mechanical valve replacement (4) Estimated glomerular filtration rate (eGFR) by Cockcroft-Gault formula less than 15 ml/min/1.73m2, or CKD stage V / end-stage kidney disease (ESKD) (5) Chronic liver disease with Child-Turcotte-Pugh score 7 points or higher (6) Pregnancy or breastfeeding (7) Poor adherence to medications (8) Inability to perform proper self-care (9) Inability to provide an informed consent

Design outcomes

Primary

Measure	Time frame
Anti-factorXa activity Pre-dose Anti-factorXa level,Anti-factorXa activity Post dose between 2-4 hours Anti-factorXa level	—

Secondary

Measure	Time frame
Ischemic stroke 1 year Number of ischemic stroke event	—

Countries

Thailand

Contacts

Public ContactWanwarang Wongcharoen

Faculty of Medicine, Chiang Mai University

bwanwarang@yahoo.com053936793

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026